ApoA-I Mimic Peptides for Dyslipidemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing and using ApoA-I to treat atherosclerotic diseases are hindered by the protein's large size, high production costs, and stability issues during storage and delivery.
Innovation Solution
Development of 22- to 29-residue peptides, known as ApoA-I Mimics, which mimic the activity of ApoA-I and are simpler and more cost-effective to produce, comprising specific amino acid sequences that form amphipathic helices for treating dyslipidemia and cardiovascular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant ApoA-I is produced and administered to treat atherosclerotic disease, then therapeutic effect is achieved, but production cost increases and manufacturing complexity increases
Solution Approach 1:
The patent creates simplified peptide copies (22-29 residues) that mimic the key functional properties of full-length ApoA-I (243 residues). These peptide copies replicate the amphipathic helix structure and cholesterol efflux capability without requiring complex recombinant protein production, thereby reducing manufacturing cost while maintaining therapeutic effect
Solution Approach 2:
The invention extracts only the essential functional elements from the full-length ApoA-I protein - specifically the amphipathic helical structure and key amino acid residues responsible for cholesterol interaction - and isolates them as standalone peptides. This extraction eliminates the need to produce the entire 243-residue protein, significantly simplifying manufacturing
2Reliability
If recombinant ApoA-I is produced and administered to treat atherosclerotic disease, then therapeutic effect is achieved, but device complexity increases
Solution Approach 1:
The patent creates simplified peptide copies (22-29 residues) that mimic the key functional properties of full-length ApoA-I (243 residues). These peptide copies replicate the amphipathic helix structure and cholesterol efflux capability without requiring complex recombinant protein production, thereby reducing manufacturing complexity while maintaining therapeutic effect
Solution Approach 2:
The invention segments the full-length ApoA-I protein into smaller, independent peptide units containing only the essential functional residues. This segmentation transforms a complex 243-residue protein production challenge into simpler peptide synthesis, reducing manufacturing complexity while preserving the therapeutic mechanism
3Ease of operation
If recombinant ApoA-I is stored and delivered, then therapeutic delivery is achieved, but stability deteriorates
Solution Approach 1:
The patent employs short peptide sequences (22-29 residues) that are inherently more stable during storage and delivery compared to full-length recombinant proteins. These peptides can be synthesized chemically with high purity and stability, eliminating the degradation issues associated with storing and transporting complex recombinant ApoA-I while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ApoA-I Mimics effectively enhance HDL cholesterol levels and reverse cholesterol transport, providing a viable alternative to recombinantly produced ApoA-I for treating dyslipidemia and related disorders.
Implementation Method 1
comprising specific amino acid sequences that form amphipathic helices for treating dyslipidemia and cardiovascular disorders
Implementation Method 2
The ApoA-I Mimics effectively enhance HDL cholesterol levels and reverse cholesterol transport
Data Source
AI summary
Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.